88 related articles for article (PubMed ID: 2337876)
1. Tumor cell concentration and tumor burden in relation to histopathologic subtype and other prognostic factors in early stage Hodgkin's disease. The Danish National Hodgkin Study Group.
Specht L; Lauritzen AF; Nordentoft AM; Andersen PK; Christensen BE; Hippe E; Hou-Jensen K; Nissen NI
Cancer; 1990 Jun; 65(11):2594-601. PubMed ID: 2337876
[TBL] [Abstract][Full Text] [Related]
2. Tumor burden as the most important prognostic factor in early stage Hodgkin's disease. Relations to other prognostic factors and implications for choice of treatment.
Specht L; Nordentoft AM; Cold S; Clausen NT; Nissen NI
Cancer; 1988 Apr; 61(8):1719-27. PubMed ID: 3349432
[TBL] [Abstract][Full Text] [Related]
3. Tumour burden as the main indicator of prognosis in Hodgkin's disease.
Specht L
Eur J Cancer; 1992; 28A(12):1982-5. PubMed ID: 1419295
[TBL] [Abstract][Full Text] [Related]
4. Histopathologic grading of nodular sclerosis Hodgkin's disease. Lack of prognostic significance in 254 surgically staged patients.
Hess JL; Bodis S; Pinkus G; Silver B; Mauch P
Cancer; 1994 Jul; 74(2):708-14. PubMed ID: 8033052
[TBL] [Abstract][Full Text] [Related]
5. Changes over the course of time in histological subclassification of Hodgkin's disease in Denmark.
Lauritzen AF; Specht LK; Nissen NI; Hou-Jensen K
Dan Med Bull; 1991 Feb; 38(1):84-7. PubMed ID: 2026054
[TBL] [Abstract][Full Text] [Related]
6. Tumour burden in early stage Hodgkin's disease: the single most important prognostic factor for outcome after radiotherapy.
Specht L; Nordentoft AM; Cold S; Clausen NT; Nissen NI
Br J Cancer; 1987 May; 55(5):535-9. PubMed ID: 3300762
[TBL] [Abstract][Full Text] [Related]
7. Progression-free survival of early interim PET-positive patients with advanced stage Hodgkin's lymphoma treated with BEACOPP
Borchmann P; Haverkamp H; Lohri A; Mey U; Kreissl S; Greil R; Markova J; Feuring-Buske M; Meissner J; Dührsen U; Ostermann H; Keller U; Maschmeyer G; Kuhnert G; Dietlein M; Kobe C; Eich H; Baues C; Stein H; Fuchs M; Diehl V; Engert A
Lancet Oncol; 2017 Apr; 18(4):454-463. PubMed ID: 28236583
[TBL] [Abstract][Full Text] [Related]
8. Disappearance of prognostic significance of histopathological grading of nodular sclerosing Hodgkin's disease for unselected patients, 1972-92.
van Spronsen DJ; Vrints LW; Hofstra G; Crommelin MA; Coebergh JW; Breed WP
Br J Haematol; 1997 Feb; 96(2):322-7. PubMed ID: 9029020
[TBL] [Abstract][Full Text] [Related]
9. Independent prognostic impact of tumour-infiltrating macrophages in early-stage Hodgkin's lymphoma.
Gotti M; Nicola M; Lucioni M; Fiaccadori V; Ferretti V; Sciarra R; Costanza M; Bono E; Molo S; Maffi A; Croci GA; Varettoni M; Frigeni M; Pascutto C; Arcaini L; Bonfichi M; Paulli M; Cazzola M
Hematol Oncol; 2017 Sep; 35(3):296-302. PubMed ID: 27060262
[TBL] [Abstract][Full Text] [Related]
10. Prognostic factors in Hodgkin's disease stage III with special reference to tumour burden.
Specht L; Nissen NI
Eur J Haematol; 1988 Jul; 41(1):80-7. PubMed ID: 3402591
[TBL] [Abstract][Full Text] [Related]
11. A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease.
Hasenclever D; Diehl V
N Engl J Med; 1998 Nov; 339(21):1506-14. PubMed ID: 9819449
[TBL] [Abstract][Full Text] [Related]
12. Grades of nodular sclerosis (NSI-NSII) in Hodgkin's disease. Are they of independent prognostic value?
Wijlhuizen TJ; Vrints LW; Jairam R; Breed WP; Wijnen JT; Bosch LJ; Crommelin MA; van Dam FE; de Koning J; Verhagen-Teulings M
Cancer; 1989 Mar; 63(6):1150-3. PubMed ID: 2917317
[TBL] [Abstract][Full Text] [Related]
13. [A retrospective analysis of the treatment results in Hodgkin's disease in a radiotherapy clinic].
Mjaaland I; Ganser D; Freitag EM; Bohndorf W
Strahlenther Onkol; 1994 Sep; 170(9):516-23. PubMed ID: 7524173
[TBL] [Abstract][Full Text] [Related]
14. [Feasibility study of application of international prognostic score on prediction of prognosis for advanced Hodgkin's lymphoma].
Fu XH; Wang SS; Huang Y; Wang B; Huang HQ; Zhang L; Sun XF; Xu RH; Lin TY
Ai Zheng; 2006 Aug; 25(8):1013-8. PubMed ID: 16965685
[TBL] [Abstract][Full Text] [Related]
15. Hodgkin's disease and age.
Specht L; Nissen NI
Eur J Haematol; 1989 Aug; 43(2):127-35. PubMed ID: 2792320
[TBL] [Abstract][Full Text] [Related]
16. [Combined-modality therapy for 150 cases of early-stage Hodgkin's lymphoma].
Niu Y; Shi YK; He XH; Feng FY; Zhou LQ; Gu DZ
Zhonghua Zhong Liu Za Zhi; 2008 Aug; 30(8):630-4. PubMed ID: 19102946
[TBL] [Abstract][Full Text] [Related]
17. [Prognostic factors of malignant lymphoma].
Masaki N; Ikeda H; Matayoshi Y; Murayama S; Fujita M; Kozuka T
Gan No Rinsho; 1989 Oct; 35(13):1591-5. PubMed ID: 2685396
[TBL] [Abstract][Full Text] [Related]
18. Clinical presentation, course, and prognostic factors in lymphocyte-predominant Hodgkin's disease and lymphocyte-rich classical Hodgkin's disease: report from the European Task Force on Lymphoma Project on Lymphocyte-Predominant Hodgkin's Disease.
Diehl V; Sextro M; Franklin J; Hansmann ML; Harris N; Jaffe E; Poppema S; Harris M; Franssila K; van Krieken J; Marafioti T; Anagnostopoulos I; Stein H
J Clin Oncol; 1999 Mar; 17(3):776-83. PubMed ID: 10071266
[TBL] [Abstract][Full Text] [Related]
19. Intensive treatment strategies in advanced-stage Hodgkin's lymphoma (HD9 and HD12): analysis of long-term survival in two randomised trials.
von Tresckow B; Kreissl S; Goergen H; Bröckelmann PJ; Pabst T; Fridrik M; Rummel M; Jung W; Thiemer J; Sasse S; Bürkle C; Baues C; Diehl V; Engert A; Borchmann P;
Lancet Haematol; 2018 Oct; 5(10):e462-e473. PubMed ID: 30290903
[TBL] [Abstract][Full Text] [Related]
20. Review of British National Lymphoma Investigation studies of Hodgkin's disease and development of prognostic index.
Haybittle JL; Hayhoe FG; Easterling MJ; Jelliffe AM; Bennett MH; Vaughan Hudson G; Vaughan Hudson B; MacLennan KA
Lancet; 1985 Apr; 1(8435):967-72. PubMed ID: 2859421
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
